Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Dermatitis. 2010;21(1):59-60 ... nystatin powder, A+D Ointment (Schering-Plough Kenilworth, NJ), and three different topical clotrimazole creams, with no improvement. Several vaginal potassium ...

Weaning patients with less-potent topical corticosteroids (10/0 hydrocortisone or desonide cream) or topical calcineurin inhibitors (1% pimecrolimus) may minimize flares (Oppel, Pavicic ...

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Q) I’VE had a rash on my forehead for six months. For the first couple, I used a steroid cream but was then told not to any ...

less well known is the fact that she lives with eczema and uses Opzelura cream to treat it. Featured alongside Moore in the ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Dermatologists have warned that applying adult skincare products and alcohol-based creams on babies puts them at risk of skin ...